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Mitochondria play an essential role in cell survival by providing energy, calcium buffering, 28 
and regulating apoptosis. A growing body of evidence shows that mitochondrial dysfunction 29 
and its consequences, including impairment of the mitochondrial respiratory chain, excessive 30 
generation of reactive oxygen species, and excitotoxicity, play a pivotal role in the 31 
pathogenesis of different diseases such as neurodegenerative diseases, neuropsychiatric 32 
disorders, and cancer. The therapeutical role of flavonoids on these diseases is gaining 33 
increasing acceptance.  Numerous studies on experimental models have revealed the 34 
favorable role of flavonoids on mitochondrial function and structure. This review highlights 35 
the promising role of baicalin and its aglycone form, baicalein, on mitochondrial function and 36 
structure with a focus on its therapeutic effects. We also discuss their chemistry, sources and 37 
bioavailability.  38 
Keywords: Antioxidant, Baicalin, Baicalein, Flavonoid, Mitochondria. 39 
 40 
1. Introduction 41 
Baicalein (5, 6, 7-trihydroxyflavone) and baicalin (syn. baicalein 7-O-β-D-glucuronic 42 
acid) are the principal components found among 30 other flavonoid derivatives in the roots of 43 
Scutellaria baicalensis Georgi (Scutellariae radix) (skullcap), known as huangqin in Chinese 44 
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traditional medicine [1]. Baicalin and its aglycon Baicalein have been attracting growing 45 
interest from pharmaceutical, cosmetic, and food industries due to their excellent biological 46 
action. In particular, these two flavonoids have shown anti-inflammatory effects and 47 
improvement of mitochondrial dysfunction [2], while a combination strategy 48 
with baicalin or baicalein as chemotherapeutic adjuvants has been revealed to lead to 49 
favourable anticancer activity targeting assorted cancer lines and relevant signalling 50 
pathways [3]. 51 
Mitochondria, the cytoplasmic double-membraned organelles which take a 52 
fundamental role in cell physiology, produce energy through formation of adenosine 53 
triphosphate (ATP) by oxidative phosphorylation. This leads to the t .ransfer of electrons via 54 
the electron transport chain (ETC), consisting of approximately 80 different polypeptides 55 
structured into five trans-membrane protein complexes (I-V). In addition, mitochondria are 56 
involved in the apoptotic process and the production of reactive oxygen species (ROS) [4]. 57 
Therefore, adequate mitochondrial function is vital to many processes including energy 58 
homeostasis, apoptosis, and metabolic signalling pathways as well as cytosolic calcium 59 
homeostasis and lipid biosynthesis in cells [5,6]. Furthermore, the most recent research has 60 
disclosed that the role of mitochondria is much greater in cellular events and disease 61 
pathology than was previously known. The  body of evidence  suggests that 62 
mitochondrial dysfunction is associated with a large number of diseases, such as age-related 63 
neurodegenerative disorders, e.g. Parkinson's disease and Alzheimer's disease [7]; cancer [8], 64 
arrhythmia and cardiomyopathy [9]; inflammation-related diseases such as sepsis [10]; 65 
gastrointestinal disorders e.g. autism spectrum disorder (ASD) [11], obesity and diabetes, in 66 
which liver steatosis and insulin resistance is developed by mitochondrial damage [12,13]; 67 
Although the mechanisms underlying mitochondrial disorders are not entirely understood, 68 
there is a need for new treatment agents. 69 
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In this regard, natural compounds have always been an attractive target for the 70 
discovery of new drug candidates, and a number of flavonoid derivatives have been 71 
demonstrated to be effective in preventing mitochondrial damage. For instance; myricitrin, a 72 
flavonoid isolated from Myrica cerifera, demonstrated a protective effect on MPP(+)-73 
induced mitochondrial dysfunction in SN4741 cells [14], while quercetin, luteolin, and 74 
epigallocatechin gallate were shown to prevent cellular apoptosis  by restoring the 75 
mitochondrial membrane potential (MMP) as well as inhibiting caspase-3 activity [15]. 76 
Similarly proanthocyanidins, as polyphenolic bioflavonoid derivatives, were found to 77 
improve hydrogen peroxide (H2O2) induced mitochondrial dysfunction by means of 78 
endorsing the MMP and respiratory chain complex IV, and decreasing free radical generation 79 
by mitochondria [16]. Application of hesperidin, a main flavanone derivative in Citrus 80 
species, led to an increase in mitochondrial complex I-IV enzymatic activity [17]. Taking this 81 
information on flavonoids into account, the focus of this paper is to review baicalin and 82 
baicalein as bioactive flavonoid derivatives, referring to their chemistry, herbal sources, 83 
bioavailability, and effects on mitochondrial dysfunction. Within this frame, a general 84 
introduction to mitochondria and its functions will be also covered. 85 
 86 
2. The Chemistry of Baicalein and Baicalin 87 
Flavonoids are one of the most extensively studied groups of polyphenolic natural 88 
products [18, 19]. The first of their two major structural units is biosynthetically derived from 89 
the acetate pathway, giving rise to the phenolic ring moiety (ring-A) of their 15 carbon 90 
skeleton structure (Fig 1) [20]. The remaining 9-carbon skeleton is derived from the shikimic 91 
acid pathway, yielding an aromatic ring (ring-B) and a 3-carbon chain as in the common 92 
cinnamic or caffeic acid derivatives. Upon joining these two structural units , different 93 
structural possibilities emerge: in the first instance the three carbon linking chain may cyclise 94 
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to form the third ring (ring-C) (as found in flavones, flavonols, and flavanones) or remain in 95 
acyclic form to give rise to chalcones.  A double bond may be introduced in the C2-C3 96 
position of ring-C to form sub groups such as flavones and flavonols, the latter defined by a 97 
hydroxyl group at the olefinic C-3 position of ring-C which is absent in flavones.In the 98 
absence of the C2-C3 double bond  other groups like flavans and flavanons emerge to 99 
represent other flavonoid sub groups.  100 
The simplest flavone compound is represented by chrysin (Fig 1), where the basic 101 
meta-substituted hydroxyl groups on the A-ring are retained. Remarkably and unlike many 102 
flavonoids, chrysin has no hydroxyl substitution on ring-B. Certain biological activities have 103 
been attributed to this unique structural feature, such as the protecting non-cancerous cell 104 
from tumor necrosis factor-α [21]. If a hydroxyl group is added to the C-6 position of chrysin,  105 
baicalein (5,6,7-trihydroxyflavone, Fig. 1) is formed as a trihydroxy derivative. The 106 
biosynthetic conversion of chrysin to baicalein has been mimicked in the laboratory through a 107 
multiple-step synthetic approach [22]. Flavonoids also diversify through glycosylation, 108 
mostly through O-linkage as represented by baicalin which carries a glucuronic acid moiety 109 
at the C-7 hydroxyl position of baicalein (Fig. 1). The most prominent structural feature of 110 
baicalein and baicain is the presence of a di-ortho hydroxyl functional group on ring-A. This 111 
feature of polyphenolic compounds is the marker for efficient metal chelation and free radical 112 
scavenging properties [23, 24] as well as enzyme inhibition [21, 25, 26]. The reported 113 
antioxidant properties of baicalein and its chelation of divalent metal ions are attributed to 114 
these structural features [27]. 115 
 116 
3. Sources of Baicalein and Baicalin 117 
To date, by far the most thoroughly studied source of baicalein is the root of the well-118 
known Chinese medicinal plant (Chinese skullcap, Huang Qin in Chinese), Scutellaria 119 
6 
 
baicalensis Georgi (Lamiaceae). While baicalein was found to be the major active principle 120 
of this traditional medicinal plant, baicalin was another active component. Baicalein, with its 121 
derivatives, exists as a principal constituent of another oriental medicinal plant, S. radax [28]. 122 
Since baicalein is also the main component of the American skullcap, S. lateriflora, [29] it is 123 
believed to be present in the various species of the genus Scutellaria. Baicalein, along with 124 
chysin and glucoside derivatives, has also been isolated from the seeds and various other 125 
parts of a popular Asian medicinal plant, Oroxylum indicum [30, 31]. Due to the popularity of 126 
baicalein and baicalin as potential therapeutic agents, a number of studies in recent years 127 
have focused on the development of suitable methods for the detection and quantification of 128 
these compounds in crude drug preparations. The most widely used methods range from 129 
simple thin layer chromatography [32, 33] to the various application modes of high 130 
performance liquid chromatography [34-37]. 131 
 132 
4. Bioavailability of Baicalein and Baicalin 133 
One major hindrance in the clinical application of baicalein and baicalin is their low 134 
aqueous solubility and poor oral bioavailability. It has been reported that once baicalein is 135 
absorbed, it is quickly metabolized to give rise to baicalin and baicalein 6-O-sulfate in the 136 
blood [38, 39]. Given the 5-OH position of flavones in a chelated form with the closely 137 
located C-4 ketone functional group, the observed preference of baicalein metabolic products 138 
for the C-6 and C-7 positions is somehow expected. Numerous studies have also shown that 139 
baicalein undergoes extensive glucuronidation within the intestinal wall and liver following 140 
oral administration in both rats and humans [40-42]. Taiming and Xuehua [43] further note 141 
the variation in baicalein and baicalin absorption sites within the gastrointestinal tract of rats. 142 
While baicalin was found to be moderately absorbed in the stomach and poorly in the small 143 
intestine and colon, baicalein was well absorbed in stomach and small intestine and relatively 144 
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less in colon. Their study also indicated that bile could excrete baicalin while significantly 145 
promoting the absorption of baicalein. Even after intravenous administration of baicalein in 146 
rats, 75.7% of the dose was found to be circulating as its conjugated metabolites [44]. In this 147 
study, the absolute absorption of baicalein following an oral route was calculated to be 40% 148 
while the relative absorption for baicalin was 65% in comparison. Overall, this and other 149 
studies [45] clearly demonstrated that baicalin can be detected in the blood of animals 150 
immediately after administration of baicalein orally or intravenously. About 90% of baicalein 151 
administered to animals is now known to be metabolized to baicalin [46].  152 
Tian et al. [47] have attempted to study the pharmacokinetic profiles of baicalein in monkeys 153 
by administering various does via oral and intravenous routes. The study revealed that the 154 
absolute bioavailability of baicalein ranges from 13.1% to 23.0% across different doses.  155 
More recently, Li et al. [48] studied the pharmacokinetic properties, the safety and 156 
tolerability of baicalein and bacalin, after single-dose administration (doses of baicalein 157 
ranging from 100 to 2800 mg) in 72 healthy Chinese subjects included in a Phase I, 158 
randomized, double-blind trial. The results showed that pharmacokinetic profile was 159 
characterized by a median Tmax of 0.75-3.5 h and 0.5-3 h, respectively, followed by a 160 
multiphasic profile with a t₁/₂ of 1.90-15.01 h and 4.22-10.80 h, respectively. The total 161 
urinary clearance of baicalein and baicalin was <1%. Approximately 27% of baicalein was 162 
eliminated as unchanged drug in feces. Moreover, baicalein resulted to be safe and well 163 
tolerated. In fact, only 11 mild treatment-related adverse events were observed, which were 164 
resolved without further treatment and no serious adverse events occurred. In addition to 165 
these data, no signs of toxicity in the liver or kidney were registered. The authors concluded 166 
that the favorable safety profile and pharmacokinetic properties warrant further clinical 167 
studies for baicalein. These conclusions agree with those earlier obtained by Kim et al. that  168 
studied the in vitro antiallergic properties and the in vivo dermal application skin toxicity of 169 
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the aqueous extract of S. baicalensis, using β-hexosaminidase assay in rat basophilic 170 
leukemia cells (RBL-2H3), and BALB/c mice, New Zealand white rabbits (to perform the 171 
acute dermal irritation/corrosion test), and Hartley guinea pigs (to estimate the safety S. 172 
baicalensis for topical application), respectively. β-Hexosaminidase release in the cell model 173 
system was markedly decreased following the treatment. It also ameliorated antigen-induced 174 
ear swelling compared with the control group in BALB/c mice. In the toxicological studies, 175 
S. baicalensis extract did not induce any dermal irritation/corrosion in rabbits or skin 176 
sensitization in guinea pigs [49].  177 
All these data, taken together, showed a safety profile of S. baicalensis extract and its 178 
components and warrant further investigations to improve dissolution and oral bioavailability 179 
of bacailein as the main bioactive component of S. baicalensis extract. 180 
To effectively deliver baicalein, which is characterized by poor aqueous solubility, several 181 
solubility enhancement techniques have been developed as spray freeze drying and solvent 182 
evaporation method for preparing solid dispersions of baicalein with Pluronic F68 [50]. 183 
Specific brain targeting by intravenous injection was successful via incorporation of bacalein 184 
into tocol nanostructured lipid carriers [51]. Other approaches to enhance the bioavailability 185 
of both baicalein and baicalin have been attempted through formulation, including the use of 186 
nanocrystals [52,53]; self-microemulsifying drug delivery systems [54]; hydroxypropyl-β-187 
cyclodextrin [55]; nanostructured lipid carriers [56]; the combined use of phospholipid 188 
complexes and self-emulsifying microemulsions [15]; and solid lipid nanoparticles [57]. 189 
 190 
5. Mitochondria: a Brief Overview  191 
Mitochondria are the main production site for ATP in animal cells. This is due to the 192 
work of the electron transfer chain (ETC) and complex V (ATP synthase) enzyme activity in 193 
the inner mitochondrial membrane, which, through the process of oxidative phosphorylation, 194 
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produce an electrochemical gradient utilized in the synthesis of ATP from adenosine 195 
diphosphate (ADP) and inorganic phosphate (Pi).  ETC deals with electrons from NADH and 196 
FADH2, released in the tricarboxylic acid cycle (the so-called Krebs cycle). By accepting 197 
electrons each complex of the mitochondrial ETC (with exception of complex II) pumps 198 
protons from the matrix side to the mitochondrial intermembrane space where they 199 
accumulate,  consequently decreasing pH and increasing the difference in charge between the 200 
matrix side and the intermembrane space (increasing the membrane potential, Δψ). The 201 
protons mostly return to the matrix side through complex V, which utilizes the force 202 
generated by the proton flux to produce ATP from ADP and Pi [58-60]. Ubiquinone 203 
(coenzyme Q10) and cytochrome c (cyt c) are electron carriers from complexes I and II to 204 
complex III and from complex III to complex IV respectively [61, 62]. Ubiquinone is 205 
responsible for the transfer of two electrons from complexes I or II to complex III, and cyt c 206 
transfer one electron at a time to complex IV. Ubiquinone is free in the inner mitochondrial 207 
membrane and readily soluble in such apolar environments [61]. Cardiolipin is the 208 
phospholipid that binds cyt c to the inner mitochondrial membrane and is responsible for the 209 
movement of this protein between the complexes [63, 64]. Cardiolipin is necessary because 210 
cyt c is not soluble in that apolar membrane. In complex IV, oxygen (O2) is converted to 211 
water (H2O) by accepting an electron and proton from cardiolipin-associated cyt c [64].  The 212 
presence of O2 is necessary to fulfill energetic demands for certain mammalian cells, for 213 
instance, neurons, muscular fibers, glandular cells, and hepatocytes. O2 is responsible for the 214 
consumption of Krebs cycle products, and of those electrons carried from glycosis to the 215 
mitochondria by the electron shuttles (namely, malate-aspartate shuttle and glycerol-3-216 
phosphate) [59-60]. Without O2 (as observed during anoxia and at moderated levels during 217 
hypoxia), those NADH and FADH2 molecules originating in the Krebs cycle and glycolysis 218 
10 
 
electrons would accumulate, decreasing the rate of Krebs cycle and, consequently, the 219 
production of ATP [60, 65, 66].  220 
Even though the ETC and complex V are necessary to produce ATP, the ETC is the 221 
major site of reactive oxygen species (ROS) production, such as, the superoxide anion radical 222 
(O2-), which may give rise to H2O2 after dismutation by Mn-superoxide dismutase (the 223 
mitochondrial isoform) [67-71]. H2O2 is able to react with free iron (Fe2+) or copper (Cu+) 224 
ions (Fenton chemistry reaction) generating the unstable and reactive free radical, OH [72]. 225 
ETC produces ROS constantly and, together with other systems, such as the microsomal 226 
cytochrome P450 enzymes (CYP450), produces a considerable amount of O2- which should 227 
be converted to H2O2 to avoid excessive damage to such biomolecules as proteins (some 228 
enzymes are very sensitive to O2-, including catalase (CAT), aconitase and α-ketoglutarate 229 
dehydrogenase from the Krebs cycle), lipids (mainly membrane phospholipids), DNA and 230 
RNA [72]. H2O2 is converted to H2O by CAT or glutathione peroxidase (GSH) enzymes; 231 
however, it is capable of crossing biomembranes due to its solubility in lipids, spreading the 232 
pro-oxidant signal originating in mitochondria to other cellular compartments, and there 233 
giving rise to OH through a Fenton chemistry reaction [72, 73]. Actually, H2O2 is 234 
considered to be, among other ROS, a messenger that participates in the regulation of 235 
signaling pathways necessary for the maintenance of cellular homeostasis, including cell 236 
metabolism and proliferation [74-77]. 237 
In addition to the enzymatic defenses mammalian cells possess non-enzymatic 238 
antioxidant defenses, for example reduced glutathione (GSH), vitamins, and bioactive 239 
molecules that may protect cells from reactive species and free radicals [72]. However, the 240 
amount of such defenses (both enzymatic and non-enzymatic) may vary according to several 241 
factors, including sex, age, diet, and exposure to pollutant chemicals [78, 79].  For example, 242 
GSH levels are significantly decreased by fasting [80]. 243 
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Mitochondria also play a pivotal role in cell death regulation by releasing cyt c into 244 
the cytosol when exposed to certain deleterious conditions, for example, higher 245 
concentrations of pro-oxidant molecules, increased intracellular Ca2+ ions and free fatty acid 246 
concentrations [81, 82]. Likewise, mitochondria controlled cell death (the so-called intrinsic 247 
apoptotic pathway) is necessary during development and maintenance of tissue homeostasis 248 
throughout life [82]. The normal shape of the animal body is a consequence of the activation 249 
of physiological apoptosis in addition to other molecular aspects. Reduced mitochondrial cyt 250 
c present in the cytosol reacts with APAF-1 (Apoptotic Protease Activating Factor - 1), ATP 251 
(or dATP), and pro-caspase-9, which is autoactivated. The assembly of APAF-1, ATP/dATP, 252 
cyt c, and pro-caspase-9 constitutes the apoptosome, a multimeric complex able to activate 253 
procaspases and to regulate the onset of apoptosis [82-84]. Activated caspase-9 (initiator 254 
caspase) cleaves and activates caspase-3, which is known as the effector caspase due to be 255 
responsible for the breakage of specific cellular targets, such as cytoskeleton proteins and 256 
enzymes (PARP – Poly ADP Ribose Polymerase, for example) [82]. This is a programmed 257 
cell death; it is very controlled and does not lead to inflammation because there is no release 258 
of cytosol content to the extracellular environment [85]. The release of cyt c to the cytosol 259 
occurs by a specific stimulus dependent on a channel that is formed in mitochondrial 260 
membranes, the so-called mitochondrial permeability transition pore (mPTP) or 261 
mitochondrial outer membrane permeabilization (MOMP). This channel consists of the C 262 
subunit of the mitochondrial ATP synthase (in the inner mitochondrial membrane), the 263 
voltage-dependent anion channel-1 (VDAC1, outer membrane channel), the adenine 264 
nucleotide translocase-1 (ANT-1, inner membrane channel), cyclophilin D (Cyp D, in the 265 
mitochondrial matrix), among other molecules [82, 86]. Cyt c is released together with other 266 
proapoptotic factors, such as Smac/Diablo, endonuclease G, apoptosis inducing factor (AIF), 267 
and serine protease OMI/HtrA2 [86].  268 
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The role of mPTP has been demonstrated as being important during regulated 269 
necrosis, and the control of apoptosis depends on MOMP [86]. MOMP is regulated by both 270 
anti- and proapoptotic factors of the Bcl-2 (B-cell lymphoma 2) protein family. The proteins 271 
of this family can be classified according to the number and structure of their Bcl-2-272 
homology domains (namely BH1-4). The BH3-only proapoptotic protein activation depends 273 
on a panoply of cell stress conditions. Once activated, they induce the oligomerization of 274 
proapoptotic proteins, e.g. Bax and Bak, and their insertion into the mitochondrial outer 275 
membrane, thereby triggering MOMP. On the other hand, multi-BH domain proteins, for 276 
instance Bcl-2, Bcl-XL, and Mcl-1, inhibit MOMP by binding to proapoptotic proteins 277 
[87].Extracellular signals may induce cell death through the extrinsic apoptotic pathway [88]. 278 
This is observed in the case of inflammation, in which the extracellular levels of chemicals 279 
such as the tumor necrosis factor-α (TNF-α), Fas ligand (FasL), and TNF-related apoptosis-280 
inducing ligand (TRAIL) bind to membrane receptors and trigger cell death by activation of 281 
caspase-8 [89]. Such pro-inflammatory molecules belong to the TNF family, which bind to 282 
death receptors on the cell surface and activate them, leading to cell death through a 283 
mitochondria independent pathway [90]. 284 
When the mitochondrial damage is excessive (it may be observed by quantifying the 285 
amount of cyt c released to the cytosol, as well as through quantification of ATP and 286 
mitochondrial enzyme activities), the cells cannot sustain the apoptotic pathway due to 287 
lacking the ATP required to maintain apoptosome formation and activity [82,84,86]. Then, 288 
the cells die through necrosis, with the consequence of releasing cell components into the 289 
extracellular space and triggering inflammation [72]. Also, depending on the redox 290 
parameters of the environment, cyt c may be oxidized and thus unable to participate in the 291 
formation of apoptosome. Thus apoptosis fails and cells die by necrosis [91, 92].  292 
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Overall, the maintenance of the cellular bioenergetic state is of crucial importance and a 293 
challenge to be administrated — not only to maintain cellular functions, but also to allow cell 294 
death to occur without generalized damage to other tissue components. 295 
 296 
6. The Effects of Baicalein and Baicalin on Mitochondrial Function and Dynamics  297 
The exact mechanism by which baicalein exerts beneficial effects on human health is 298 
not completely understood yet, but as illustrated above it plays an apparent role in 299 
mitochondrial protection. 300 
In an in vitro experimental model, baicalein (6.25 and 12.5µM) protected 301 
mitochondria from SH-SY5Y neuroblastoma cells against 6-hydroxydopamine (6-OHDA)-302 
induced toxicity and also prevented loss of cell viability [93]. Additionally, pretreatment with 303 
baicalein (2h before 6-OHDA treatment) alleviated the increase in reactive oxygen species 304 
(ROS) production and alterations in cellular morphology. Interestingly, baicalein was 305 
effective in blocking the effect of 6-OHDA on the mitochondrial membrane potential (MMP; 306 
ΔΨm). The authors suggested that baicalein protected mitochondria from loss of potential via 307 
a redox-dependent mechanism, since pretreatment with 1 mM N-acetylcysteine (NAC) 308 
induced a very similar effect. Zhang et al. [94] also demonstrated that pre-incubation of PC12 309 
cells with baicalein at 5-40 µM for 12 h protected mitochondria from loss of MMP induced 310 
by H2O2, as well as caused an increased in the contents of Bcl-2 and a decrease in the levels 311 
of Bax. Furthermore, baicalein (10-40 µM) pretreatment (1 h) prevented the loss of MMP in 312 
immortalized human epidermal melanocyte cells (PIG1) exposed to H2O2 [95]. In another 313 
work, co-treatment with baicalein (10-40 µM) avoided loss of MMP induced by rotenone in 314 
PC12 cells [94]. Loss of MMP has been linked to caspase activation and triggering of cell 315 
death, as previously reviewed [82]. Indeed, baicalein blocked caspase activation in the 6-316 
OHDA-treated SH-SY5Y cells and effectively protected cells from apoptosis [93]. Liu et al. 317 
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[95] reported that baicalein (10-40 µM) prevented caspase activation and death of PIG1 cells 318 
induced by H2O2 by exerting mitochondrial protection through a mechanism that depends, at 319 
least in part, on Bcl-2 protein and the inhibition of cytochrome c release to the cytosol. 320 
Hence, baicalein avoided mitochondrial damage consequently inhibiting cell death via the 321 
intrinsic apoptotic pathway. 322 
In another study, baicalein (10 µg/mL) induced an increase in the immunocontent of 323 
Mn-superoxide dismutase (Mn-SOD) enzyme by a mechanism dependent on nuclear factor 324 
erythroid 2 [NF-E2]-related factor 2 (Nrf2) activation in Chinese hamster lung fibroblast 325 
(V79-4) cells exposed to H2O2 [95]. Additionally, baicalein increased Bcl-2 expression and 326 
caused a decrease in the levels of phosphorylated Bcl-2 and Bax. The phosphorylated form of 327 
Bcl-2 is in an inactive state and fails to inhibit apoptosis. On the contrary, Bax is activated 328 
under phosphorylation, and migrates to mitochondria to induce cytochrome c release from the 329 
organelle [82-88]. Mn-SOD is responsible for the conversion of O2- to H2O2 in the 330 
mitochondrial matrix [98, 99]. The expression of Mn-SOD is regulated mainly by Nrf2 and 331 
the nuclear factor-B (NF-B) in situations of oxidative stress and/or inflammation [100-332 
102]. Down-regulation of Mn-SOD is associated with cardiac disease, neonatal lethality, and 333 
neurodegeneration [103, 104]. On the other hand, up-regulation of Mn-SOD has been linked 334 
to cellular protection against several chemical challenges [105, 106]. Thus, Mn-SOD up-335 
regulation through bioactive compounds would be an interesting strategy to prevent damage 336 
resulting from chemical stress on mitochondria. Indeed, authors described decreased ROS 337 
production levels in mitochondria from baicalein-treated V79-4 cells exposed to H2O2 [97]. 338 
Bioenergetic parameters associated to mitochondrial function were analyzed by He et 339 
al. [107]. The authors investigated the effect of subacute baicalein treatment (30 or 100 340 
mg/kg for 27 days) on mitochondrial dysfunction induced by chronic cerebral hypoperfusion 341 
(CCR). Baicalein increased the respiration control ratio (RCR), the consumption of ADP, and 342 
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the production of ATP. However, baicalein did not alter O2 consumption. Furthermore, 343 
baicalein improved MMP and decreased mitochondrial ROS production. Baicalein was also 344 
effective in avoiding morphological changes induced by CCR, as assessed through the 345 
analyses of the degree of mitochondrial swelling. On the other hand, baicalein only partially 346 
alleviated the effects induced by rotenone on mitochondria isolated from rat brain [96]. 347 
Baicalein was not effective in preventing the decrease in O2 consumption induced by 348 
rotenone, and it did not improve the ATP produced/O2 consumed ratio. However, the authors 349 
found that mitochondria incubated with baicalein (0.5 or 5 µM) for 30 min before rotenone 350 
exposure presented higher ATP levels than the control. Additionally, baicalein (5 µM) 351 
alleviated ROS production and blocked mitochondrial swelling induced by rotenone in vitro. 352 
Taken together, this data demonstrates that baicalein may be an important protective 353 
agent regarding mitochondrial function. Nonetheless, the beneficial effects of baicalein 354 
depend on the nature of the toxic agent, as seen in the experimental model using rotenone as a 355 
mitochondrial stressor [96]. Rotenone is a specific complex I (NADH dehydrogenase) 356 
inhibitor and causes enhanced mitochondrial ROS production that leads cells to apoptosis 357 
[108]. The binding of rotenone to complex I is irreversible, and treatment with baicalein did 358 
not avoid the direct effects of this toxin on mitochondrial function (as for instance electron 359 
transfer, O2 consumption, and ATP produced). Nevertheless, baicalein did act as an 360 
antioxidant by decreasing ROS detection, as assessed through DCFH-DA assay [96]. 361 
Therefore, baicalein may sustain cellular bioenergetics in the event of redox impairment by 362 
protecting mitochondrial systems involved in ATP production. 363 
Baicalein was also tested in an experimental model of pulmonary carcinogenesis 364 
induced by benzo[a]pyrene [109]. The authors found that baicalein treatment at 12 mg/kg 365 
once a week for 16 weeks alleviated the effects of benzo[a]pyrene (BaP; 50 mg/kg twice a 366 
week for four weeks) on rat lung mitochondria with regards to ROS production, 367 
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morphological changes (swelling of the organelle), enzyme activities (isocitrate 368 
dehydrogenase - ICDH, α-ketoglutarate dehydrogenase – α-KDH, succinate dehydrogenase - 369 
SDH, malate dehydrogenase - MDH, NADH dehydrogenase, and cytochrome c oxidase), 370 
lipid peroxidation in mitochondrial membranes, and reduced glutathione (GSH) content. 371 
Additionally, the authors demonstrated that antioxidant enzymes in mitochondria were 372 
modulated by baicalein pre-treatment. Post-treatment with baicalein was only partially 373 
effective in protecting mitochondria from BaP-induced toxicity in that experimental model. 374 
This data demonstrates that baicalein protected mitochondrial function by maintaining 375 
bioenergetic homeostasis related to the Krebs cycle (CK, the so called tricarboxylic acid 376 
cycle – TCA) and mitochondrial electron transfer chain (METC) system. In the same work, 377 
baicalein blocked BaP-induced carcinogenesis by triggering apoptosis in lung cells through a 378 
mechanism dependent on mitochondrial integrity, since apoptosis is an ATP-dependent 379 
process. In this context, baicalein protected the lung against BaP-induced carcinogenesis by 380 
sustaining the apoptotic machinery associated with mitochondrial function and integrity. 381 
The effects of baicalein alone (0.5-5.0 µM) on mitochondria isolated from rat brain 382 
were investigated by Li et al. [96]. The authors found that baicalein induced a decrease in the 383 
amount of O2 consumed in state 4 (respiration occurring in the absence of ADP or inhibitory 384 
agents) without altering ATP production, consequently increasing RCR and the 385 
mitochondrial P/O ratio. This effect may be linked to decreased electron leakage from 386 
mitochondria, an event closely related to ROS production by the organelle [108]. Baicalein 387 
alone did not alter ATP levels, but decreased ROS production by isolated mitochondria. 388 
Additionally, baicalein alone did not change mitochondrial morphology according to analyses 389 
of the swelling of the organelles [96]. Taken together, these data demonstrate that baicalein 390 
has a potential role as an agent, which is able to amplify mitochondrial function, ensuring 391 
increased rates of ATP production in situations of stress. 392 
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Baicalin, another flavonoid isolated from Scutellaria baicalensis Georgi, presents 393 
antioxidant and anti-inflammatory properties. Baicalin (120 mg/kg for 30 days) decreased 394 
mitochondrial damage induced by streptozotocin in an animal model of diabetes, protecting 395 
mitochondria from morphological alterations associated with mitochondrial pathology 396 
(changes in the volume of the organelle, damaged membranes, and decreased number of 397 
cristae) induced by streptozotocin (STZ), as assessed through transmission electron 398 
microscope analyses [111]. Additionally, baicalin increased the number of mitochondria and 399 
citrate synthase enzyme activity in diabetic rats. Nonetheless, the mechanism by which 400 
baicalin induced mitochondrial biogenesis is not yet clear. The effect of baicalin was found to 401 
be stronger in the presence of metformin, indicating that this flavonoid may be utilized as a 402 
therapeutic agent in cases of diabetes. 403 
In another study, pre-treatment with baicalin at 200 mg/kg (at 24h and 1h) protected 404 
the organelle from hepatic ischemia/reperfusion (I/R) in an experimental model in rats [112]. 405 
Baicalin was effective in preventing mitochondrial swelling induced by experimental I/R. 406 
Additionally, baicalin blocked caspase activation and avoided cell death in rat liver. Baicalin 407 
also decreased the inflammation that resulted from I/R by NF-B activation. NF-B has been 408 
implicated in both antioxidant and pro-oxidant events. However, the role of NF-B in 409 
inflammation seems to be more associated with pro-oxidant effects closely related to 410 
production of pro-oxidant molecules, for instance nitric oxide (NO) [113]. Therefore, 411 
baicalin exerted antioxidant and anti-inflammatory effects that either directly or indirectly 412 
prevented the impact of I/R on mitochondria. In fact, baicalin (1-100 mg/kg i.p. 30 min 413 
before induction of renal I/R) exerted anti-inflammatory effects in an animal model of renal 414 
I/R, by decreasing the expression of interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α 415 
(TNF-α), through a mechanism related to NF-B down-regulation [114]. The authors also 416 
demonstrated that baicalin elicited an antioxidant effect by increasing SOD enzyme activity 417 
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and decreasing the levels of lipid peroxidation markers. Additionally, baicalin decreased 418 
caspase-9 and caspase-3 activation and increased Bcl-2 expression. Therefore, baicalin was 419 
capable of ameliorating the redox environment and reducing the inflammatory signs resulting 420 
from renal I/R, inhibiting apoptosis of renal cells. 421 
Baicalin also exerted beneficial effects on mitochondrial dynamics and function in an 422 
experimental model of toxicity induced by antimycin A in rat L6 skeletal muscle cell line 423 
[113]. Cells were treated with baicalin (50 µg/mL) for 1 h and then were exposed to 424 
antimycin A (100 µg/mL) for 24 h. Baicalin improved cell viability, ATP production, and 425 
MMP, whereas it led to a decrease in mitochondrial O2- production in antimycin A-treated 426 
cells. Furthermore, baicalin increased the immunocontent of peroxisome proliferator-427 
activated receptor gamma coactivator 1-alpha (PGC-1α) by 40%, which is a regulator of 428 
mitochondrial biogenesis and is up-regulated in cases of pathological hypertrophy and heart 429 
failure [116]. Moreover, PGC-1α increases the expression of superoxide dismutase 2 (SOD2; 430 
Mn-SOD) and of glutathione peroxidase-1 (GPX1), enzymes responsible for removing O2- 431 
and H2O2, respectively [117]. Overall, PGC-1α is a master regulator in mitochondrial 432 
biogenesis and remodeling, as well as being involved in ROS detoxification, and baicalin acts 433 
as a protective agent to mitochondria, at least in part, through up-regulation of PGC-1α and 434 
its associated signaling pathway.  435 
Yan and Liu [118] demonstrated that direct treatment of mitochondria isolated from 436 
rat brain with baicalin (0.8-1.5 mM) decreased state 3 and RCR in an animal model of 437 
hypoxia induced by hypobaric situations. On the other hand, baicalin did not exert any effect 438 
on state 4 and on MMP. Thus, baicalein did not prevent the mitochondrial changes elicited by 439 
hypoxia. The authors did not quantify ROS or RNS production to verify whether baicalin 440 
would exert an antioxidant effect in a situation in which ROS and RNS may be generated at 441 
higher rates. Such effects may be a result of exposing isolated mitochondria to the herbal 442 
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monomer baicalin. It is possible that different results would be obtained from treating the 443 
animals before induction of hypoxia. Interestingly, baicalin (1-25 µM) did not exert any 444 
protective effect against rotenone-induced loss of viability in RGC-5 cells (a cell line with 445 
some ganglion cell characteristics) [119]. 446 
 447 
7. The role of baicalin and baicalein in modulating cell signaling pathways and the 448 
impact on mitochondria  449 
There are several reports demonstrating the effects of baicalein on different cell signaling 450 
pathways in a myriad of experimental models involving both in vitro and in vivo studies. 451 
However, some works did not demonstrate whether there is a causative link between 452 
signaling pathways modulation and mitochondrial physiology maintenance. Some research 453 
groups clearly described that by triggering a certain signaling pathway it would lead to 454 
mitochondrial alterations that will or will not culminate in cell survival. Therefore, we 455 
focused to discuss in this Section only reports in which the authors studied cell signaling 456 
pathways that are involved with mitochondrial function and/or quality and that is associated 457 
to cell fate.  458 
Liu et al. showed that baicalein (20 mg/kg i.p., 30 min before and 2 and 4 h after onset of 459 
ischemia) did not alter infarct volume in permanent middle cerebral artery occlusion 460 
(MCAO) induced in rats, but was effective in protecting rat brain regions (total brain, cortex, 461 
and subcortex) against transient MCAO [120]. Additionally, baicalein did prevent caspase-3 462 
activation in MCAO experimental model. In the same work, authors demonstrated that 463 
baicalein (0.035 – 3.5 µM, 2h before induction of oxygen and glucose deprivation, OGD – an 464 
experimental model utilized to mimic ischemia in vitro) preserved neuronal viability and 465 
blocked cytotoxicity induced by OGD. Baicalein at 35 µM was not effective in protecting 466 
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primary cultured cortical neurons against OGD. Baicalein (3.5 µM, 2h before induction of 467 
OGD) prevented the increased in ROS in cultured neuronal cells. However, a treatment with 468 
10 µM LY294002 (an inhibitor of PI3K) 30 min before OGD partially suppressed the effects 469 
of baicalein on ROS production in that experimental model. Furthermore, baicalein 470 
pretreatment inhibited the increase in 3-nitrotyrosine content in neurons exposed to OGD. 471 
However, LY294002 treatment abolished the protective effects of baicalein regarding 472 
nitrosative stress. Authors found that baicalein did induce phosphorylation of Akt, GSK-3β, 473 
and PTEN (the phosphatase and tensin homolog deleted on chromosome 10). Akt becomes 474 
activated after phosphorylation, but PTEN is inactivated after being phosphorylated. PTEN, 475 
when activated, is a negative regulator of Akt pathway. Activated PTEN would lead to 476 
apoptosis by a mitochondria-related mechanism that accounts with release of cytochrome c 477 
from the organelle [121-123]. Then, baicalein protected cultured neuronal cells by activation 478 
of the PI3K/Akt pathway and inactivation of PTEN, resulting in increased phosphorylation of 479 
Bad at Ser136 (a pro-apoptotic protein) and, consequently, decreased release of cytochrome c 480 
from mitochondria, since dephosphorylated Bad plays a role in activating the MPTP during 481 
early apoptosis. Actually, baicalein pretreatment decreased OGD-induced cytochrome c 482 
release from mitochondria through a PI3K/Akt axis-dependent fashion. Thus, a protective 483 
effect of baicalein involved the activation of protein kinases that mediate cell survival 484 
through maintenance of mitochondrial function and quality. The mechanism by which 485 
baicalein reduced infarction volume in vivo was not addressed in that work.  486 
In another study, Pallast et al. showed that baicalein (300 mg/kg, i.p. just before MCAO 487 
induction in mice) prevented the increase in the amount of apoptosis-inducing factor (AIF) in 488 
cell nucleus [124]. AIF translocation from mitochondria to nucleus is related to apoptosis 489 
induction through a caspase-independent cell death [125-127]. AIF translocation plays a role 490 
in triggering cell death through apoptosis in MCAO experimental models, as previously 491 
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demonstrated [126,128,129]. Furthermore, authors observed that the translocation of AIF to 492 
the nucleus was somewhat associated to the increase in the expression of 12/15-LOX (12/15-493 
lipoxygenase) enzyme. Indeed, 12/15-LOX colocalizes with AIF in the nucleus of neuronal 494 
cells after MCAO induction, as demonstrated by that research group. However, baicalein 495 
treatment did inhibit 12/15-LOX and AIF expression in vivo. To better analyze the 496 
mechanism by which baicalein exerted neuronal protection, authors performed in vitro assays 497 
utilizing HT22 cells (a neuronal cell line derived from murine hippocampus). Authors found 498 
that baicalein (10 µM) co-administration protected HT22 neuronal cells from glutamate-499 
induced toxicity by inhibiting the interaction of 12/15-LOX with membranes of mitochondria 500 
and endoplasmic reticulum (ER). Additionally, baicalein treatment suppressed the effect of 501 
glutamate in causing leakage of luminal ER proteins to the cytosol, indicating a role for 502 
baicalein as an inhibitor of disturbances in the membrane of ER in this experimental model. 503 
Baicalein also inhibited translocation of AIF from mitochondria to the nucleus in cultured 504 
HT22 neuronal cells. The aggregation of 12/15-LOX near the cell nucleus (the so called 505 
perinuclear region, which is rich in ER and mitochondria) seems to play a role in the leakage 506 
of proteins commonly found in the lumen of ER, since blockade of 12/15-LOX aggregation 507 
lead to decreased levels of ER luminal protein in the cytosol, as demonstrated in that 508 
experimental model and by other researchers [130]. A clear role for 12/15-LOX in causing 509 
mitochondrial damage was not addressed in that work, and the authors did state that more 510 
investigations are needed to better comprehend the exact mechanism by which baicalein 511 
counteracted the 12/15-LOX-mediated organelle damage in neurons. A previously published 512 
work by van Leyed et al. also demonstrated that baicalein (300 mg/kg, i.p. 5 min before 513 
induction of MCAO) protected mice from the deleterious effects elicited by ischemia by a 514 
similar way when compared to animals in which ALOX15 gene was knocked down, 515 
demonstrating a role for 12/15-LOX in the mechanism of neuronal damage triggered by 516 
22 
 
MCAO [129]. Recently, Cui et al. found that baicalein (30 mg/kg, intravenous injection) co-517 
treatment alleviated the effects of MCAO in rat brain (striatum and cortex) [132]. Baicalein 518 
decreased the contents of 12/15-LOX, p38 (phosphorylated form), and cytosolic 519 
phospholipase A2 (cPLA2, a pro-inflammatory enzyme that releases arachidonic acid from 520 
biomembranes increasing its bioavailability to the LOX pathway, as previously published by 521 
Farooqui and Horrocks [133]. However, a link with mitochondrial function was not analyzed 522 
in those works.     523 
Baicalein modulated the ERK1/2 pathway in an in vitro experimental model of 524 
Parkinson’s disease (PD) utilizing SH-SY5Y neuroblastoma cells. Song et al. reported that 525 
pretreatment with baicalein (25 – 100 µM for 1h) prevented ERK1/2 activation induced by 526 
rotenone [134]. Prolonged ERK1/2 activation may play a role in apoptosis induction, as 527 
described elsewhere [135-137]. Furthermore, baicalein reduced Bax levels in rotenone-528 
treated cells. Consequently, baicalein blocked loss of MMP and suppressed caspase-3 529 
activation, causing inhibition of apoptosis in SH-SY5Y cells exposed to rotenone. By 530 
blocking loss of MMP induced by rotenone, baicalein prevented the increase in mitochondrial 531 
permeability that would lead to cytochrome c release to cytosol, which will culminate in cell 532 
death through apoptosis. Zhang et al. demonstrated that baicalein (50 – 200 µM for 12h) 533 
pretreatment was able to increase cell viability of PC12 cells exposed to 6-OHDA [138]. 534 
Baicalein activated Nrf2 leading to increased expression of HO-1 and causing cytoprotection. 535 
In addition, authors described that baicalein increased the activity of antioxidant enzymes, as 536 
for instance catalase (CAT) and SOD in 6-OHDA-treated PC12 cells. Nonetheless, a role for 537 
baicalein as a mitochondrial protective agent was not demonstrated in that work. 538 
Recently, Qi et al. described that baicalein (2 and 4 mg/kg, i.p. once a day during 7 539 
weeks) was effective in protecting rat hippocampus in an experimental model of diabetes 540 
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(induced with STZ) [139]. STZ treatment did lead to increased acetylcholinesterase (AChE) 541 
activity and decreased choline acetylase (ChAT), but baicalein significantly alleviated the 542 
alterations in such enzymes in that experimental model. Exposure to STZ induced a decrease 543 
in the levels of phosphorylated PI3K and Akt protein kinases, as well as increased the 544 
contents of phosphorylated GSK-3β (glycogen synthase kinase-3β). Baicalein suppressed the 545 
effects of STZ on such protein kinases, causing a pro-survival signal that culminates with 546 
decreased activation of both caspases-9 and -3. Baicalein also ameliorated cognitive deficits 547 
elicited by STZ in that experimental design. Therefore, baicalein exerted a protective effect in 548 
vivo by activating protein kinases that trigger pro-survival effects by inhibiting apoptosis 549 
probably by a mitochondria-related pathway, since the mediators of the intrinsic apoptotic 550 
pathway were modulated by baicalein treatment.   551 
8. Baicalin versus baicalein 552 
Baicalein is an aglycone derivative from baicalin. Then, there are structural 553 
similarities between these two flavonoids. However, baicalin and baicalein may exert 554 
different effects on mammalian cells, as will be discussed here considering only the authors 555 
that analyzed baicalin and baicalein in the same manuscript. 556 
Ikemoto et al. tested the ability in baicalin and baicalein in inducing antitumor effects 557 
on bladder cancer cell lines (KU-1, EJ-1, and MBT-2) and found that baicalin exerted a 558 
stronger antitumor activity when compared to baicalein, since the concentration of baicalin 559 
necessary to cause 50% inhibition of tumor growth was 3.4 µg/mL and the concentration of 560 
baicalein was 30 µg/mL [140]. Mitochondrial parameters were not assessed in that work, but 561 
the success of baicalin and baicalein in inducing tumor cell growth inhibition may be 562 
associated to induction of cell death, as demonstrated by others and discussed in the present 563 
work. Evidently, it is necessary to perform more analyses comparing the efficiency of these 564 
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flavonoids in inducing cancer cell growth inhibition and to examine the mechanism by which 565 
baicalin and baicalein exerted antitumor activity. Indeed, Zhou et al. reported that baicalin or 566 
baicalein treatment induced apoptosis in human breast cancer cells (MCF-7 and MDA-MB-567 
231 cell lines) by activating the ERK/p38 MAPK signaling pathway and triggering the 568 
intrinsic apoptotic pathway associated to mitochondria PTP opening [141]. The combination 569 
of the flavonoids (50 µM baicalin more 25 µM baicalin for 24h or 48h) exerted a stronger 570 
effect in the induction of cell death in that experimental model. The combination of baicalin 571 
and baicalein induced an increase in the expression of Bax, a pro-apoptotic protein that is 572 
involved in the triggering of cytochrome c release from mitochondria [82]. The combination 573 
of the two flavonoids also caused caspase-9 and caspase-3 activation, clearly demonstrating a 574 
role for mitochondria in the process of ongoing apoptosis in that experimental model. The 575 
levels of the anti-apoptotic protein Bcl-2, which inhibits MPTP and, consequently, the release 576 
of cytochrome c, were decreased by the combination of baicalin and baicalein. Then, baicalin 577 
and baicalein, when combined, induce a stronger antitumor effect on breast cancer cell lines 578 
by activating the intrinsic apoptotic pathway through a mechanism that depends, at least in 579 
part, on the activation of MAPK signaling pathway. A role for NF-B (which is regulated by 580 
MAPK, among other protein kinases) or another transcription factor associated to apoptosis 581 
was not described in that work. The investigation regarding the involvement of transcription 582 
factors in the apoptotic event would be very useful to better analyze the exact mechanism by 583 
which the flavonoids baicalin and baicalein elicit antitumor activity.   584 
Gao et al. found that baicalin and baicalein (10 µM for 10 min) were efficient in 585 
protecting SH-SY5Y neuroblastoma cells against H2O2-induced toxicity. Baicalin and 586 
baicalein similarly prevented the decreased in cell survival, in cell viability, and in membrane 587 
integrity elicited by H2O2 [142]. Nonetheless, baicalein induced a stronger protective effect 588 
regarding inhibition of lipid peroxidation, as assessed through measurement of 589 
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malondialdehyde (MDA) levels, when compared to baicalin-treated cells. Authors did not 590 
analyze mitochondrial parameters, but found that both baicalein and baicalin similarly 591 
prevented the increase in intracellular Ca2+ levels triggered by H2O2. The increase in 592 
intracellular Ca2+ levels may lead to augmented mitochondrial concentrations of this ion, 593 
which favors mitochondrial dysfunction (i.e. resulting in increased ROS production and 594 
oxidative and nitrosative damage to mitochondrial components) and cell death by activation 595 
of the MPTP, as previously reviewed by others [82]. Interestingly, Kyo et al. have previously 596 
demonstrated that baicalein reduced intracellular Ca2+ ions concentration with a greater 597 
potency than baicalin (> 10 µM to each flavonoid) [143]. The effects of the flavonoids on 598 
intracellular Ca2+ were due to the inhibition elicited by baicalein and baicalin on 599 
phospholipase C (PLC) activity. Then, by inhibiting PLC, baicalin and baicalein decreased 600 
the intracellular Ca2+ concentration in C6 glioma cells. Thus, this may be considered an 601 
indirect effect of baicalin and baicalein that may participate in mitochondrial protection 602 
against, for example, chemically induced oxidative stress in vitro. In the work by Gao et al., 603 
the antioxidant effects of baicalin and baicalein were attributed to its structure, since baicalin 604 
presents an o-di-hydroxyl and baicalein contains an o-tri-hydroxyl group [142]. Then, the 605 
antioxidant effects elicited in such experimental model may be a result from its chemical 606 
structure. Additionally, the incubation with such flavonoids were very short (10 min), leading 607 
to the conclusion that the effects seen in that work were not due to the activation of 608 
transcription factors and the resulting increase in the expression of antioxidant enzymes.  609 
A comparison regarding the effects of baicalin and baicalein on mitochondria was 610 
made by Chang et al. [144]. Authors found that baicalin or baicalein alone decreased cell 611 
viability on hepatoma cell lines (Hep G2, Hep 3B, and SK-Hep1) and caused MMP 612 
disruption at a similar way. Baicalin (50 µM for 48h) induced a stronger effect on impairing 613 
MMP in Hep G2 cells when compared to baicalein at the same concentration. On the other 614 
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hand, baicalein (50 µM for 48h) was more effective in causing loss of MMP in Hep 3B cell 615 
line than baicalin in that experimental model. Surprisingly, baicalin or baicalein decreased 616 
cellular GSH content in hepatoma cell lines, indicating a pro-oxidant role for such flavonoids. 617 
Additionally, it may be a consequence of the active metabolism of xenobiotics by glutathione 618 
S-transferase (GST) enzymes. However, the authors did not analyze such parameters in that 619 
work. In this context, the differences among the effects elicited by baicalin and baicalein may 620 
be associated to the cell type. Moreover, it remains to be analyzed whether these two 621 
flavonoids would exert different effects regarding mitochondrial protection in future works. 622 
Takahashi et al. reported that baicalin or baicalein treatment induced cell death in 623 
human pancreatic cells (BxPC-3, HPAF-II, MIAPaCa-2, and Panc-1 cell lines) [145]. 624 
However, the effect elicited by baicalein was stronger than that induced by baicalin at the 625 
same dose tested. Baicalein induced a dose-dependent (1 – 50 µM) effect inhibiting tumor 626 
cells growth and decreasing cell viability. Baicalein was especially stronger in inhibiting cell 627 
proliferation in BxPC-3 cell line, in which baicalein at 1 – 5 µM exerted an inhibitory effect 628 
on cell proliferation that was only partially achieved by baicalin at 50 µM. Authors did not 629 
compared these two flavonoids in another parameters, as for instance mitochondrial function, 630 
but demonstrated that baicalein exerted its antitumor activity by activating apoptosis through 631 
a mechanism that involved down-regulation of Mcl-1, an anti-apoptotic protein that may bind 632 
Bak (a pro-apoptotic protein), causing increased resistance to apoptosis, as demonstrated by 633 
the authors. Bak interacts with mitochondria causing opening of the MPTP and consequent 634 
release of cytochrome c to cytosol, triggering the intrinsic apoptotic pathway, as reviewed 635 
elsewhere [82]. Reducing Mcl-1 levels is an important step towards apoptosis in tumor cells 636 
because it was previously described that the down-regulation of Bcl-2 or Bcl-xL anti-637 
apoptotic proteins is not sufficient to elicit apoptosis [146,147]. Then, Mcl-1 regulation by 638 
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baicalein is an interesting strategy to induce cell death in tumor cells by activation of the 639 
mitochondria-related apoptotic mechanism.    640 
Recently, Wang et al. published that baicalein was more efficient than baicalin in 641 
decreasing cell proliferation at the same concentrations tested (10, 20, and 50 µM for HCT-642 
116, and 20 and 50 µM for HT-29 colorectal cancer cell lines) [148]. Moreover, authors 643 
found that the aglycone-rich fraction (ARF) of Scutellaria baicalensis extract exerted a 644 
stronger effect in inducing loss of MMP in such cell lines when compared to the baicalin 645 
fraction (BF). ARF contains both baicalein and wogonin flavonoids, but not baicalin. 646 
Additionally, ARF decreased Bcl2 expression more intensely than BF. Other parameters 647 
associated to mitochondrial function or related to the role of this organelle in apoptosis were 648 
not investigated in that work.   649 
Utilizing human leukocytes, Shen et al. observed that baicalein (IC50  2-3 µM) 650 
exerted a stronger antioxidant effect than baicalin (IC50  5-26 µM) in suppressing 651 
extracellular ROS accumulation induced by N-formyl-methionyl-leucyl-phenylalanine 652 
(fMLP) or phorbol-12-myristate-13-acetate (PMA) depending on the cell type (neutrophils or 653 
mononuclear cells) [149]. Baicalein also presented a higher ability in inhibiting the 654 
accumulation of intracellular ROS when compared to baicalin at the same concentrations 655 
tested (1 – 100 µM). Baicalein (100 µM) also prevented the increase in cytosolic Ca2+ ions 656 
concentration induced by fMLP and AlF4- (an activator of G-protein), but failed when 657 
thapsigargin was utilized to trigger Ca2+ release from intracellular store. Baicalin (10 – 100 658 
µM) was not effective in preventing the increase in intracellular Ca2+ ions levels in this 659 
experimental model. Even though the authors did not investigate whether there is a causative 660 
link between the decrease in ROS accumulation and the reduced levels of cytosolic Ca2+ ions 661 
in that work, one may argue that the decreased concentration of Ca2+ ions in the cytosol may 662 
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prevented an increase in ROS production and its posterior release for the extracellular 663 
environment, since mitochondria (among other cellular compartments and protein systems) 664 
produce more ROS in conditions in which the levels of intracellular Ca2+ ions are augmented. 665 
The mechanism by which baicalein prevented both ROS and Ca2+ ions accumulation in 666 
leukocytes remains to be fully understood, but may account with a role for mitochondria in 667 
buffering Ca2+ ions and an antioxidant role for baicalein in blocking ROS accumulation by a 668 
direct (chemical structure-related antioxidant capacity) or indirect (through the activation of 669 
transcription factors associated to the antioxidant defenses in mammalian cells) manner. 670 
Interestingly, Lee et al. described that baicalein and baicalin exerted protection in primary 671 
cultured rat brain neurons against MK-801 or glucose deprivation, but failed to prevent an 672 
increase in NO at any concentration tested (0.35 – 10 µM) [150]. Actually, baicalein at 35 673 
µM induced neurotoxic effects and increased NO production in glucose-deprived cells. 674 
Furthermore, baicalin slightly increased LDH (lactate dehydrogenase) release from primary 675 
neurons maintained under normal glucose concentration (33 mM). Also, baicalin (10 µM) 676 
was not effective in preventing the increase in LDH release induced by glucose deprivation in 677 
that experimental model. On the other hand, baicalein and baicalin alone did attenuate the 678 
increase in intracellular Ca2+ ions induced by glutamate/NMDA treatment. As discussed in 679 
this Section, by preventing an augmentation in cytosolic Ca2+ ions concentration, baicalein 680 
and baicalin may exert an indirect antioxidant role on mitochondria by blocking, for example, 681 
loss of MMP and mitochondrial ROS production. 682 
Baicalin was not efficient counteracting the toxic effects of 6-OHDA or rotenone in 683 
PC12 (pretreatment with baicalin at 12 – 200 µM for 12h) [138] and SH-SY5Y (pretreatment 684 
with baicalin at 10 – 100 µM for 1h) [134] neuronal cells.  685 
9. Conclusion 686 
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A growing body of evidence demonstrates that mitochondrial dysfunction plays an 687 
important role in the pathogenesis of different diseases, such as Parkinson's disease and 688 
Alzheimer's disease, cardiovascular diseases, cancer, and metabolic disorders. With respect to 689 
this, much attention has been paid to find new therapeutic agents for mitochondrial 690 
dysfunction-related disorders. It is well-known that oxidative stress plays an important role in 691 
these disorders. Abundant scientific evidence shows that natural polyphenolic antioxidants 692 
have beneficial effects on mitochondrial damage; among them, much attention has been paid 693 
to baicalin and baicalein. This review has demonstrated that baicalin and baicalein mitigate 694 
mitochondrial damage through redox-dependent mechanisms. In addition, it has shown that 695 
baicalin and baicalein protect mitochondria from oxidative stress both in vitro and in vivo. It 696 
has also revealed that the presence of hydroxyl moieties in the chemical structure of baicalin 697 
and baicalein play a pivotal role in their protective effects against oxidative stress in 698 
mitochondria. In conclusion, baicalein and baicalin exert protective (or preventive) effects on 699 
mitochondria in different biological systems. This action depends on several factors, such as 700 
concentration and duration of treatment, the chemical characteristics of the toxic 701 
agent/stressor, and the biological conditions of the target. However, a search on the Clinical 702 
Trials Gov database 1 with keywords “baicalein” and “baicalin” has shown that there are only 703 
two recruited clinical studies concerning these natural compounds and, therefore, it can be 704 
difficult to make a clear decision about their clinical impacts.  705 
Finally, we recommend that future studies should be performed to: 706 
- Enhance the bioaccessibility and bioavailability of baicalein and baicalin through new 707 
delivery forms, such as nanocrystallization, nanoemulsion, baicalin-loaded liposomes, 708 
and solid lipid nanoparticles of baicalin. 709 
                                                             




- Carry out toxicity studies for ascertaining the most effective and non-toxic doses of 710 
these compounds for future studies and the potential side and adverse effects  711 
- Ascertain the most effective doses for future clinical studies, regarding the beneficial 712 
effects of baicalein and baicalin against mitochondrial dysfunction-related disorders. 713 
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Figure 2. A summary of the effects of baicalein on mitochondrial function and dynamics 1174 
and apoptosis. Baicalein is a polyphenol that may exert mitochondrial protection 1175 
leading to prevention of chemically induced apoptosis in several experimental models. 1176 
Baicalein increases mitochondrial activity and improves redox-related aspects in the 1177 
organelle. Furthermore, baicalein inhibits changes in mitochondrial function and 1178 
dynamics that would lead to apoptosis, as for instance cytochrome c release and loss of 1179 
mitochondrial membrane potential (MMP). Baicalein also activates Nrf2, the master 1180 
regulator of the redox environment in mammalian cells, causing an increase in the 1181 
expression of the antioxidant enzyme Mn-SOD, which converts O2- to H2O2 in the 1182 
mitochondrial matrix. There are several efforts to elucidate the complete mechanism by 1183 
which baicalein exerts its cytoprotective effects, but it clearly involves an improvement 1184 





Figure 3. A summary of the effects of baicalin on mitochondrial function and dynamics 1188 
and apoptosis. Baicalin improves mitochondrial function, i.e. augments ATP production 1189 
and citrate synthase activity (which belongs to the tricarboxylic acid cycle – the so called 1190 
Krebs cycle). Baicalin exerted antioxidant effects on mitochondria by decreasing ROS 1191 
production and lipid peroxidation in mitochondrial membranes, as well as activating 1192 








Table 1. Summary of the in vitro effects of baicalein and baicalin on mitochondrial 1199 


















6-OHDA ↓ ROS production, ↑ MMP*, ↓ apoptosis  93 
Baicalei
n 





H2O2 ↑ MMP*, ↓ Bax content, ↑ Bcl-2 content 94 
Baicalei
n 





↑ MMP*, ↓ cytochrome c release, ↑ Bcl-
2 content, ↓ apoptosis 95 
Baicalei
n 















↓ mitochondrial ROS production, ↓ 
cytochrome c release, ↓ p-Bcl-2 content, 
↓ p-Bax content, ↑ Nrf2 activity, ↑ Mn-







↑ MMP*, ↓ O2
- production, ↑ ATP 
production, ↑ PGC-1α content 115 
Baicalin 






rotenone No alterations detected. 119 
* Baicalein or baicalin were effective in preventing loss of MMP. ** Baicalein at 40 µM did not 





Table 2. Summary of the in vivo effects of baicalein and baicalin on mitochondrial 1205 








Rat CCR model;  
Baicalein 30 or 100 
mg/kg.day-1 for 27 
days post-CCR 
induction, oral route 
↑ respiration control rate, ↑ MMP*, ↑ ADP 
consumption, ↑ ATP production, ↓ mitochondrial 




↓ mitochondrial ROS production, ↓ mitochondrial 
sweeling, ↑ VDAC expression, ↑ activity of CK 109 
53 
 
(50 mg/kg b.w. 
B(a)P); Baicalein 12 
mg/kg once a week  
enzymes (ICDH, α-KDH, SDH, and MDH), ↑ 
activity of METC enzymes (NADH dehydrogenase 
and cytochrome c oxidase) 
Baicalin 
Rat diabetes model 
(STZ); Baicalin 120 
mg/kg for 30 days 
Baicalin protected mitochondria from STZ-induced 
morphological changes. ↑ number of mitochondria, ↑ 
citrate synthase activity 111 
Baicalin 
Rat hepatic I/R 
model; Baicalin 200 
mg/kg 24h and 1h 
before I/R induction 
↓ mitochondrial swelling, ↓ NF-kB activation, ↓ 
caspase activation 112 
Baicalin 
Rat renal I/R model; 
Baicalin 1-100 
mg/kg i.p. 30 min 
before I/R induction 
↑ Bcl-2 content, ↓ Bax content, ↓ caspase-9 and caspase-3 
activation 114 
* Baicalein or baicalin were effective in preventing loss of MMP. 
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